245 related articles for article (PubMed ID: 21780334)
1. Summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease.
White CM; Greene L
J Manag Care Pharm; 2011 Jun; 17(5 Suppl):S1-15. PubMed ID: 21780334
[TBL] [Abstract][Full Text] [Related]
2. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease.
Baker WL; Coleman CI; Kluger J; Reinhart KM; Talati R; Quercia R; Phung OJ; White CM
Ann Intern Med; 2009 Dec; 151(12):861-71. PubMed ID: 20008762
[TBL] [Abstract][Full Text] [Related]
3. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
4. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
Unger T
Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
6. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Yusuf S
Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
[TBL] [Abstract][Full Text] [Related]
7. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
Li EC; Heran BS; Wright JM
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
10. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
11. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Böhm M; Baumhäkel M; Mahfoud F; Werner C
Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
Guthrie R
Clin Cornerstone; 2009; 9 Suppl 3():S18-26. PubMed ID: 19409352
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II and trials of cardiovascular outcomes.
Sleight P
Am J Cardiol; 2002 Jan; 89(2A):11A-16A; discussion 16A-17A. PubMed ID: 11835905
[TBL] [Abstract][Full Text] [Related]
17. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
18. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
Zimmermann M; Unger T
Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
